Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Bortezomib inhibits Burkitt's lymphoma cell proliferation by downregulating sumoylated hnRNP K and c-Myc expression.

Oncotarget - 22 Sept 2015

Suk Fat-Moon, Lin Shyr-Yi, Lin Ren-Jye, Hsine Yung-Hsin, Liao Yen-Ju, Fang Sheng-Uei, Liang Yu-Chih

Abstract excerpt

Bortezomib (Velcal) was the first proteasome inhibitor to be approved by the US Food and Drug Administration to treat patients with relapsed/refractory multiple myelomas. Previous studies have demonstrated that bortezomib inhibits tumor cell proliferation and induces apoptosis by blocking the nuclear factor (NF)-κB pathway. However, the exact mechanism by which bortezomib induces cancer cell apoptosis is still...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bortezomib
Share to Burkitt Lymphoma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Electrophoresis, Gel, Two-Dimensional

Share to Endoplasmic Reticulum Chaperone BiP

Share to Lysine

Share to Proto-Oncogene Proteins c-myc

Share to Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization

Share to Sumoylation

Source

Open in PubMed Open full text

Identifiers

PMID: 26317903
DOI: 10.18632/oncotarget.4620
PMCID: PMC4694880

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Bortezomib inhibits Burkitt's lymphoma cell proliferation by downregulating sumoylated hnRNP K and c-Myc expression.PMID 26317903Read ↗

KLF9 is a novel transcriptional regulator of bortezomib- and LBH589-induced apoptosis in multiple myeloma cellsSemantic proximity Read ↗

The role of proteasome inhibition in the treatment of malignant and non-malignant hematologic disordersSemantic proximity Read ↗

Emerging therapies targeting the ubiquitin proteasome system in cancerSemantic proximity Read ↗

Novel Proteasome Inhibitors to Overcome Bortezomib ResistanceSemantic proximity Read ↗

Proteasome-associated deubiquitinases and cancerSemantic proximity Read ↗

Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress.Semantic proximity Read ↗

NEDD4L binds the proteasome and promotes autophagy and bortezomib sensitivity in multiple myelomaSemantic proximity Read ↗

Molecular Pathways: Translational Potential of Deubiquitinases as Drug TargetsSemantic proximity Read ↗

Targeting the ubiquitin‐proteasome system for cancer therapySemantic proximity Read ↗

The role of proteasomes in tumorigenesisSemantic proximity Read ↗

The role of the ubiquitin proteasome system in lymphomaSemantic proximity Read ↗

Activating KRAS, NRAS, and BRAF mutants enhance proteasome capacity and reduce endoplasmic reticulum stress in multiple myeloma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.